Parathyroid Carcinoma disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

PRTC MCID: PRT010 MIFTS: 67	Parathyroid Carcinoma (PRTC) Categories: Cancer diseases, Endocrine diseases, Genetic diseases, Rare diseases	Data Licensing For inquiries, contact: [email protected]
Genes Variations Tissues Related diseases Publications Symptoms & Phenotypes Drugs Expand all tables

Sources

Aliases & Classifications for Parathyroid Carcinoma

MalaCards integrated aliases for Parathyroid Carcinoma:

Name: Parathyroid Carcinoma ⁵⁷ ¹¹ ¹⁹ ⁴² ⁵⁸ ⁷³ ²⁸ ¹² ⁵³ ⁵ ¹⁴ ⁷⁵

Parathyroid Neoplasms ⁴² ⁵³ ⁴³ ⁷¹

Parathyroid Cancer ¹⁹ ⁴² ⁷⁵ ⁵³

Malignant Tumor of Parathyroid Gland ¹¹ ⁴² ⁷¹

Malignant Neoplasm of Parathyroid Gland ¹¹ ⁴²

Parathyroid Gland Adenocarcinoma ¹¹ ⁷¹

Carcinoma of Parathyroid Gland ¹¹ ⁴²

Parathyroid Gland Carcinoma ⁴² ¹⁶

Parathyroid Gland Cancer ¹¹ ⁴²

Parathyroid Neoplasm ¹¹ ⁷⁵

Prtc ⁵⁷ ⁷³

Malignant Neoplasm of the Parathyroid ¹¹

Malignant Parathyroid Gland Neoplasm ⁴²

Malignant Neoplasm of Parathyroid ⁴²

Malignant Parathyroid Gland Tumor ⁴²

Neoplasm of the Parathyroid Gland ⁵

Cancer of the Parathyroid Gland ⁴²

Malignant Parathyroid Neoplasm ⁴²

Malignant Tumor of Parathyroid ⁴²

Neoplasm of Parathyroid Gland ¹¹

Malignant Parathyroid Tumor ⁴²

Parathyroid Gland Neoplasm ¹¹

Parathyroid Adenocarcinoma ⁴²

Cancer of the Parathyroid ⁴²

Carcinoma, Parathyroid ³⁸

Characteristics:

Prevelance:

<1/1000000 (Europe, United States, Austria, Belgium, Bulgaria, Croatia, Czech Republic, Estonia, Finland, Germany, Iceland, Ireland, Italy, Latvia, Lithuania, Malta, Norway, Poland, Portugal, Slovakia, Slovenia, Spain, Switzerland, Netherlands, United Kingdom) 1-9/1000000 (Europe, Europe) ⁵⁸

Age Of Onset:

Adult ⁵⁸

Classifications:

MalaCards categories:
Global: Genetic diseases Rare diseases Cancer diseases
Anatomical: Endocrine diseases

See all MalaCards categories (disease lists)

ICD10: ³¹ ³²

Neoplasms

Malignant neoplasms of thyroid and other endocrine glands

Malignant neoplasm of other endocrine glands and related structures

Malignant neoplasm: Parathyroid gland

Orphanet: ⁵⁸

Rare endocrine diseases

Sources

Summaries for Parathyroid Carcinoma

MedlinePlus Genetics: ⁴² Parathyroid cancer is a rare cancer that usually affects people in their forties or fifties and occurs in one of the four parathyroid glands. The parathyroid glands are located in the neck and secrete parathyroid hormone, which enhances the release of calcium into the blood.In about 90 percent of cases, the early signs of parathyroid cancer are high levels of parathyroid hormone (hyperparathyroidism) and calcium (hypercalcemia) in the blood. In these cases, the cancer is described as hormonally functional because the parathyroid glands are producing excess hormone.Many individuals with hormonally functional parathyroid cancer develop hypercalcemic crisis, in which calcium levels in the blood are very high. Neurological problems can develop, including changes in mood and depression. About 30 percent of individuals with hypercalcemia due to parathyroid cancer develop kidney and skeletal problems. These problems include increased urine production (polyuria), deposits of calcium in the kidneys (nephrocalcinosis) leading to the formation of kidney stones (nephrolithiasis), bone pain, bone loss, and increased bone fractures. Abdominal pain, inflammation of the pancreas (pancreatitis), sores (ulcers) in the lining of the digestive tract, nausea, vomiting, weight loss, and fatigue are also common.About 10 percent of cases of parathyroid cancer are described as hormonally nonfunctional. In these cases, levels of parathyroid hormone and calcium are normal. The signs and symptoms of hormonally nonfunctional parathyroid cancer are related to the tumor obstructing nearby structures in the neck. These problems include difficulty swallowing (dysphagia) and speaking (dysarthria), a hoarse voice, shortness of breath (dyspnea), or vocal cord paralysis.Up to 85 percent of individuals with parathyroid survive at least 5 years after they are diagnosed. The disease recurs in approximately half of individuals. If cancer does recur, it will commonly be within 3 years of the original diagnosis and up to 78 percent of people with recurrent cancer survive at least 5 years. Hormonally nonfunctional parathyroid cancer has a lower survival rate because it is often found at a later stage, as it does not have early signs such as increased calcium and parathyroid hormone levels.In hormonally functional parathyroid cancer, death is usually caused by organ failure (usually kidney failure) due to prolonged hypercalcemia and not directly due to the tumor. In hormonally nonfunctional parathyroid cancer, the cause of death is typically related to the tumor itself, such as its impact on the function of nearby structures or its spread to other tissues (metastasis).

MalaCards based summary: Parathyroid Carcinoma, also known as parathyroid neoplasms, is related to hyperparathyroidism 2 with jaw tumors and osteitis fibrosa. An important gene associated with Parathyroid Carcinoma is CDC73 (Cell Division Cycle 73), and among its related pathways/superpathways are Signal Transduction and Neuroscience. The drugs Cinacalcet and Acetaminophen have been mentioned in the context of this disorder. Affiliated tissues include parathyroid glands located in the neck, thyroid and bone, and related phenotypes are parathyroid carcinoma and primary hyperparathyroidism

GARD: ¹⁹ A rare endocrine tumor characterized by a malignant neoplasm derived from parathyroid parenchymal cells, localized in one of the normally located parathyroid glands or other sites where parathyroid tissue may be present. Signs and symptoms are predominantly due to excess secretion of parathyroid hormone, with marked hypercalcemia and renal and bone involvement. In rare cases, the tumor may be non-functioning and only present as a palpable mass in the neck region. Recurrent laryngeal nerve paralysis is also observed. The tumor can occur sporadically or on a genetic background. The extent of invasion of adjacent structures positively correlates with the development of recurrent or metastatic disease.

Orphanet: ⁵⁸ A rare endocrine tumor characterized by a malignant neoplasm derived from parathyroid parenchymal cells, localized in one of the normally located parathyroid glands or other sites where parathyroid tissue may be present. Signs and symptoms are predominantly due to excess secretion of parathyroid hormone, with marked hypercalcemia and renal and bone involvement. In rare cases, the tumor may be non-functioning and only present as a palpable mass in the neck region. Recurrent laryngeal nerve paralysis is also observed. The tumor can occur sporadically or on a genetic background. The extent of invasion of adjacent structures positively correlates with the development of recurrent or metastatic disease.

UniProtKB/Swiss-Prot: ⁷³ These cancers characteristically result in more profound clinical manifestations of hyperparathyroidism than do parathyroid adenomas, the most frequent cause of primary hyperparathyroidism. Early en bloc resection of the primary tumor is the only curative treatment.

Disease Ontology: ¹¹ An endocrine gland cancer located in the parathyroid glands located in the neck.

Wikipedia ⁷⁵ Parathyroid cancer: Parathyroid carcinoma is a rare cancer resulting in parathyroid adenoma to carcinoma progression. It... more...

Parathyroid neoplasm: A parathyroid neoplasm is a tumor of the parathyroid... more...

More information from OMIM: 608266

Sources

Related Diseases for Parathyroid Carcinoma

Diseases related to Parathyroid Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 288)

#	Related Disease	Score	Top Affiliating Genes
1	hyperparathyroidism 2 with jaw tumors	32.0	RET MEN1 CDC73 CCND1 CASR
2	osteitis fibrosa	31.9	PTH CDC73 CASR CALCA
3	hyperparathyroidism 1	31.8	MEN1 GCM2 CDC73
4	hyperparathyroidism	31.0	RET PTH MEN1 GCM2 CDC73 CASR
5	goiter	30.7	RET LGALS3 CALCA
6	multiple endocrine neoplasia	30.7	RET PTH MEN1 CDC73 CALCA
7	ossifying fibroma	30.4	PTH MEN1 CDC73
8	thyroid carcinoma, familial medullary	30.4	RET MEN1 CALCA
9	endocrine gland cancer	30.4	RET MIR30B MIR139 APC
10	thyroid gland medullary carcinoma	30.3	RET PTH MEN1 CALCA
11	hypercalcemia, infantile, 1	30.3	PTH CASR CALCA
12	papillary carcinoma	30.3	RET MKI67 LGALS3 CALCA
13	secondary hyperparathyroidism	30.3	PTH MEN1 CXADR CASR CALCA
14	multinodular goiter	30.2	RET PTH LGALS3 CALCA
15	primary hyperparathyroidism	30.2	RET PTH MEN1 GCM2 CXADR CDC73
16	hyperphosphatemia	30.1	PTH GCM2 CASR
17	islet cell tumor	30.1	RET MEN1 CALCA
18	adenoma	30.0	RET PTH MKI67 MEN1 LGALS3 CTNNB1
19	multiple endocrine neoplasia, type i	30.0	RET PTH MIR139 MEN1 GCM2 CDC73
20	nodular goiter	30.0	RET PTH LGALS3 CALCA
21	thyroid gland follicular carcinoma	30.0	RET LGALS3 CTNNB1 CCND1 CALCA
22	inherited cancer-predisposing syndrome	30.0	RET RB1 MEN1 CDC73 APC
23	bap1 tumor predisposition syndrome	30.0	RET RB1 MEN1 CDC73 APC
24	substernal goiter	30.0	RET PTH CALCA
25	neuroendocrine tumor	29.9	RET MKI67 MEN1 CCND1 CALCA
26	parathyroid gland disease	29.9	RET PTH MEN1 GCM2 CDC73 CASR
27	familial adenomatous polyposis	29.9	CTNNB1 CCND1 APC
28	hashimoto thyroiditis	29.9	RET LGALS3 CALCA
29	rickets	29.8	PTH CASR CALCA
30	multiple endocrine neoplasia, type iia	29.8	RET PTH MIR139 MEN1 CDC73 CALCA
31	thyroid gland anaplastic carcinoma	29.6	RET LGALS3 CTNNB1 CCND1 CALCA
32	thyroid gland cancer	29.5	RET PTH MEN1 LGALS3 CTNNB1 CCND1
33	conn's syndrome	29.4	RET PTH MEN1 CTNNB1 CASR CALCA
34	parathyroid adenoma	29.3	RET PTH MEN1 LGALS3 GCM2 CXADR
35	adenocarcinoma	29.3	RET RB1 CTNNB1 CCND1 APC
36	lung cancer susceptibility 3	29.3	RB1 MIR139 CTNNB1 CCND1 APC
37	prolactinoma	29.3	MEN1 CTNNB1 CCND1
38	brain cancer	29.3	RB1 MIR139 CTNNB1 APC
39	hypoparathyroidism	29.3	RET PTH GCM2 CXADR CASR CALCA
40	meningioma, familial	29.2	RET MKI67 MEN1 CTNNB1 CCND1 APC
41	lynch syndrome	29.2	RET MIR139 MEN1 CTNNB1 CCND1 APC
42	nephrolithiasis, calcium oxalate	10.5
43	thyroid carcinoma	10.5
44	bone disease	10.5
45	rare tumor	10.4
46	chronic kidney disease	10.4
47	tetanic cataract	10.4	PTH CALCA
48	malignant ovarian brenner tumor	10.3	PTH CALCA
49	kidney disease	10.3
50	nephrolithiasis	10.3

Comorbidity relations with Parathyroid Carcinoma via Phenotypic Disease Network (PDN):

Hyperparathyroidism

Graphical network of the top 20 diseases related to Parathyroid Carcinoma:

Sources

Symptoms & Phenotypes for Parathyroid Carcinoma

Human phenotypes related to Parathyroid Carcinoma:

⁵⁸ ³⁰ (show all 38)

#	Description	HPO Frequency	Orphanet Frequency	HPO Source Accession
1	parathyroid carcinoma ⁵⁸ ³⁰	Obligate (100%)	Obligate (100%)	HP:0006780
2	primary hyperparathyroidism ⁵⁸ ³⁰	Obligate (100%)	Obligate (100%)	HP:0008200
3	hypophosphatemia ⁵⁸ ³⁰	Hallmark (90%)	Very frequent (99-80%)	HP:0002148
4	hypercalciuria ⁵⁸ ³⁰	Hallmark (90%)	Very frequent (99-80%)	HP:0002150
5	elevated circulating parathyroid hormone level ⁵⁸ ³⁰	Hallmark (90%)	Very frequent (99-80%)	HP:0003165
6	dysphagia ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0002015
7	polydipsia ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0001959
8	fatigue ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0012378
9	osteoporosis ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0000939
10	nephrolithiasis ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0000787
11	nephrocalcinosis ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0000121
12	hoarse voice ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0001609
13	weight loss ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0001824
14	fibroma ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0010614
15	uterine leiomyoma ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0000131
16	infantile hypercalcemia ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0008250
17	shortened qt interval ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0012232
18	nausea and vomiting ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0002017
19	constipation ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0002019
20	muscle weakness ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0001324
21	renal insufficiency ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0000083
22	peptic ulcer ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0004398
23	headache ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0002315
24	bone pain ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0002653
25	chondrocalcinosis ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0000934
26	renal cyst ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0000107
27	pancreatitis ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0001733
28	episodic abdominal pain ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0002574
29	renal hamartoma ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0008696
30	mandibular pain ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0200025
31	pancreatic adenocarcinoma ⁵⁸ ³⁰	Very rare (1%)	Very rare (<4-1%)	HP:0006725
32	lipoma ⁵⁸ ³⁰	Very rare (1%)	Very rare (<4-1%)	HP:0012032
33	nephroblastoma ⁵⁸ ³⁰	Very rare (1%)	Very rare (<4-1%)	HP:0002667
34	thyroid carcinoma ⁵⁸ ³⁰	Very rare (1%)	Very rare (<4-1%)	HP:0002890
35	testicular neoplasm ⁵⁸ ³⁰	Very rare (1%)	Very rare (<4-1%)	HP:0010788
36	hypercalcemia ⁵⁸ ³⁰		Obligate (100%)	HP:0003072
37	hyperparathyroidism ³⁰			HP:0000843
38	abnormality of the parathyroid morphology ⁵⁸		Very frequent (99-80%)

Clinical features from OMIM®:

608266 (Updated 08-Dec-2022)

GenomeRNAi Phenotypes related to Parathyroid Carcinoma according to GeneCards Suite gene sharing:

²⁵ (show all 19)

#	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	Increased shRNA abundance (Z-score > 2)	GR00366-A-111	9.64	MEN1
2	Increased shRNA abundance (Z-score > 2)	GR00366-A-128	9.64	MEN1
3	Increased shRNA abundance (Z-score > 2)	GR00366-A-133	9.64	APC
4	Increased shRNA abundance (Z-score > 2)	GR00366-A-134	9.64	CCND1
5	Increased shRNA abundance (Z-score > 2)	GR00366-A-152	9.64	CCND1
6	Increased shRNA abundance (Z-score > 2)	GR00366-A-153	9.64	MEN1
7	Increased shRNA abundance (Z-score > 2)	GR00366-A-172	9.64	RB1
8	Increased shRNA abundance (Z-score > 2)	GR00366-A-177	9.64	RB1
9	Increased shRNA abundance (Z-score > 2)	GR00366-A-181	9.64	RB1
10	Increased shRNA abundance (Z-score > 2)	GR00366-A-192	9.64	APC
11	Increased shRNA abundance (Z-score > 2)	GR00366-A-202	9.64	APC
12	Increased shRNA abundance (Z-score > 2)	GR00366-A-21	9.64	CCND1
13	Increased shRNA abundance (Z-score > 2)	GR00366-A-210	9.64	CCND1 RB1
14	Increased shRNA abundance (Z-score > 2)	GR00366-A-211	9.64	CCND1
15	Increased shRNA abundance (Z-score > 2)	GR00366-A-36	9.64	CCND1
16	Increased shRNA abundance (Z-score > 2)	GR00366-A-43	9.64	RB1
17	Increased shRNA abundance (Z-score > 2)	GR00366-A-47	9.64	CTNNB1 MEN1
18	Increased shRNA abundance (Z-score > 2)	GR00366-A-50	9.64	RB1
19	Increased shRNA abundance (Z-score > 2)	GR00366-A-98	9.64	MEN1

MGI Mouse Phenotypes related to Parathyroid Carcinoma:

⁴⁵ (show all 20)

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	homeostasis/metabolism	MP:0005376	10.47	APC CALCA CASR CCND1 CDC73 CTNNB1
2	nervous system	MP:0003631	10.42	APC CALCA CASR CCND1 CDC73 CTNNB1
3	growth/size/body region	MP:0005378	10.37	APC CASR CCND1 CDC73 CTNNB1 CXADR
4	neoplasm	MP:0002006	10.33	APC CALCA CCND1 CDC73 CTNNB1 LGALS3
5	renal/urinary system	MP:0005367	10.31	APC CALCA CASR CDC73 CTNNB1 CXADR
6	endocrine/exocrine gland	MP:0005379	10.29	APC CASR CCND1 CDC73 CTNNB1 CXADR
7	digestive/alimentary	MP:0005381	10.26	APC CASR CCND1 CDC73 CTNNB1 CXADR
8	cellular	MP:0005384	10.25	APC CASR CCND1 CDC73 CTNNB1 CXADR
9	normal	MP:0002873	10.24	APC CALCA CCND1 CTNNB1 GCM2 MEN1
10	cardiovascular system	MP:0005385	10.18	APC CALCA CCND1 CDC73 CTNNB1 CXADR
11	behavior/neurological	MP:0005386	10.18	APC CALCA CASR CCND1 CDC73 CTNNB1
12	immune system	MP:0005387	10.17	ADCK1 APC CASR CCND1 CDC73 CTNNB1
13	muscle	MP:0005369	10.16	APC CASR CDC73 CTNNB1 CXADR MEN1
14	liver/biliary system	MP:0005370	10.15	APC CDC73 CTNNB1 CXADR LGALS3 MEN1
15	embryo	MP:0005380	10.15	APC CALCA CDC73 CTNNB1 CXADR GCM2
16	craniofacial	MP:0005382	10.06	APC CCND1 CDC73 CTNNB1 GCM2 MEN1
17	respiratory system	MP:0005388	9.96	CALCA CCND1 CDC73 CTNNB1 CXADR LGALS3
18	skeleton	MP:0005390	9.93	APC CALCA CASR CCND1 CDC73 CTNNB1
19	mortality/aging	MP:0010768	9.83	APC CALCA CASR CCND1 CDC73 CTNNB1
20	integument	MP:0010771	9.28	APC CALCA CASR CCND1 CDC73 CTNNB1

Sources

Drugs & Therapeutics for Parathyroid Carcinoma

Drugs for Parathyroid Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 70)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Cinacalcet

Approved

Phase 4

226256-56-0

156419

Acetaminophen

Approved

Phase 4

103-90-2

1983

Tramadol

Approved, Investigational

Phase 4

27203-92-5

33741 5523

Cathine

Approved, Experimental, Illicit, Vet_approved, Withdrawn

Phase 4

14838-15-4, 492-39-7

131954576 4786 26934

Guaifenesin

Approved, Investigational, Vet_approved

Phase 4

93-14-1

3516

Codeine

Approved, Illicit

Phase 4

76-57-3, 6854-40-6

5284371 5362471

Respiratory System Agents

Phase 4

Analgesics, Opioid

Phase 4

Analgesics

Phase 4

Antipyretics

Phase 4

Antitussive Agents

Phase 4

Analgesics, Non-Narcotic

Phase 4

Chlorpheniramine, phenylpropanolamine drug combination

Phase 4

Narcotics

Phase 4

Pharmaceutical Solutions

Phase 4

Denosumab

Approved

Phase 3

615258-40-7

Cholecalciferol

Approved, Nutraceutical, Vet_approved

Phase 3

67-97-0, 1406-16-2

5280795 10883523

Choline

Approved, Nutraceutical

Phase 3

62-49-7

305

Vitamins

Phase 3

Calciferol

Phase 3

Antimetabolites

Phase 3

Hypolipidemic Agents

Phase 3

Nootropic Agents

Phase 3

Lipid Regulating Agents

Phase 3

Gastrointestinal Agents

Phase 3

Technetium Tc 99m Sestamibi

Phase 3

Nivolumab

Approved

Phase 2

946414-94-4

Ipilimumab

Approved

Phase 2

477202-00-9

Diphosphonates

Phase 2

Dihydroxyphenylalanine

Phase 2

Antineoplastic Agents, Immunological

Phase 2

Immunoglobulins

Phase 2

Immune Checkpoint Inhibitors

Phase 2

Antibodies, Monoclonal

Phase 2

Antibodies

Phase 2

Dacarbazine

Approved, Investigational

Phase 1

4342-03-4

2942 5351166

Bortezomib

Approved, Investigational

Phase 1

179324-69-7

387447 93860

Carboplatin

Approved

Phase 1

41575-94-4

10339178 38904

Paclitaxel

Approved, Vet_approved

Phase 1

33069-62-4

36314

Trastuzumab

Approved, Investigational

Phase 1

180288-69-1

Alkylating Agents

Phase 1

Antineoplastic Agents, Alkylating

Phase 1

Albumin-Bound Paclitaxel

Phase 1

Adjuvants, Immunologic

Phase 1

Interleukin-12

Phase 1

Angiogenesis Inhibitors

Phase 1

Immunologic Factors

Phase 1

Gefitinib

Approved, Investigational

184475-35-2

123631

Parathyroid hormone

Approved, Investigational

9002-64-6

Lidocaine

Approved, Vet_approved

Early Phase 1

137-58-6

3676

Interventional clinical trials:

(show all 43)

#	Name	Status	NCT ID	Phase	Drugs
1	An Assessment of the Calcimimetic Agent AMG 073 for the Treatment of Subjects With Parathyroid Carcinoma or Intractable Primary Hyperparathyroidism.	Completed	NCT00037518	Phase 4	AMG 073
2	Minimizing Narcotic Analgesics After Thyroid or Parathyroid Surgery	Completed	NCT03469310	Phase 4	Acetaminophen 500Mg Cap;Tylenol #3 Oral Tablet;Tramadol
3	Intravenous Or Topical Lidocaine And Neuromonitoring in Thyroid Surgery (IOLANT Study)	Recruiting	NCT04574947	Phase 4	Intravenous lidocaine;Intravenous placebo
4	An Intra-Subject Dose-Adjustment Study of KHK7580 for the Treatment of Hypercalcemia in Patients With Parathyroid Carcinoma or Primary Hyperparathyroidism Who Are Unable to Undergo Parathyroidectomy or Relapse After Parathyroidectomy	Completed	NCT03280264	Phase 3	KHK7580
5	An Intra-individual Titration Study of KRN1493 for the Treatment of Hypercalcemia in Patients With Parathyroid Carcinoma or Intractable Primary Hyperparathyroidism	Completed	NCT01460030	Phase 3	Cinacalcet HCl
6	18F-Fluorocholine for the Detection of Parathyroid Adenomas	Completed	NCT03764007	Phase 2, Phase 3	18F-Fluorocholine
7	Treatment of Primary Hyperparathyroidism With Denosumab and Cinacalcet.	Completed	NCT03027557	Phase 3	Cinacalcet 30 mg Tablet;Denosumab Inj 60 mg/ml
8	18F-Fluorocholine Positron Emission Tomography (PET) for the Detection of Parathyroid Adenomas	Recruiting	NCT04895631	Phase 3	18F-Fluorocholine
9	Phase III Trial Comparing 2 Diagnostic Strategies for Preoperative Localization of Parathyroid Adenoma in Primary Hyperparathyroidism:TEMP / CT With Tc99m-sestaMIBI or PET / CT With F18-choline in First Intention	Active, not recruiting	NCT04040946	Phase 3
10	A Single-arm, Multicenter, Proof-of-concept Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium Despite Recent Treatment With IV Bisphosphonates	Completed	NCT00896454	Phase 2	denosumab
11	Interest of the F18-choline as a Second Line of the Tracer for Detection of Parathyroid Adenomas	Completed	NCT02432599	Phase 2
12	Studies of Hyperparathyroidism and Related Disorders	Completed	NCT00001277	Phase 2	68Ga-Dotatate;18F-DOPA
13	DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors	Recruiting	NCT02834013	Phase 2
14	A Phase II Study to Evaluate the Effects of 177Lu-DOTATATE in Patients With Unresectable and Progressive Rare Metastatic Endocrine Carcinomas: Medullary Thyroid Cancer, Parathyroid Carcinoma, Pituitary Carcinoma, and Malignant Pheochromocytoma/Paraganglioma	Withdrawn	NCT04106843	Phase 2	Lutetium Lu 177 Dotatate
15	Phase I Trial of Dacarbazine and Bortezomib in Melanoma and Soft Tissue Sarcoma	Completed	NCT00580320	Phase 1	Dacarbazine and bortezomib
16	A Phase I Trial of Herceptin and Interleukin-12	Completed	NCT00004074	Phase 1
17	Molecular and Immunohistochemical Profiling of Tumor From Patients With Parathyroid Tumors for Evaluation of Targeted Agents	Unknown status	NCT03039439
18	Evaluation of a New CZT System for Imaging in Routine Nuclear Medicine Examination	Unknown status	NCT01084356
19	Identification of Differentially Expressed Proteins in Parathyroid Tumors and Their Clinical Correlation With the Disease	Unknown status	NCT01647503
20	Localization of Parathyroid Adenoma by Fluorocholine Positron Emission Tomography/MRI (PET/MRI): A Prospective Pilot Study	Unknown status	NCT02843542
21	Parathyroid Cancer Versus Atypical Parathyroid Neoplasm; Investigating Their Clinical Characteristics and Biological Behavior	Completed	NCT03046524
22	Use of Hypocalcemic Intraarterial Infusion Into the Thyroid/Parathyroid Bed to Localize Occult Parathyroid Adenomas	Completed	NCT00001394
23	Detection and Characterization of Circulating Tumor Cells in Patients With Malignant Pleural Mesothelioma: Towards a New Phase in the Understanding of the Natural History of This Cancer?	Completed	NCT01776385
24	Optimization and Individualization of Diagnostic Scintigraphy Protocol and Minimally Invasive Radio-guided Parathyroid Surgery Using Quantitative Analysis of Scintigraphy Results on Hybrid SPECT-CT Imaging	Completed	NCT04344886
25	The Utility of 18F-fluorocholine PET/CT in the Imaging of Parathyroid Adenomas	Completed	NCT04570033
26	Observation of Histological Changes in Parathyroid Adenomas Following High Intensity Focused Ultrasound (HIFU)Treatment Procedure: A Monocentre, Open, Uncontrolled Study	Completed	NCT01060982
27	The Feasibility of Bilateral Intermediate Cervical Plexus Block for Thyroidectomy/Parathyroidectomy Under Moderate Sedation; Retrospective Study	Completed	NCT04905641
28	Single Agent ZD-1839 (NSC-715055, IND-61187) in Patients With Advanced Head and Neck Carcinoma or Non-Small Cell Lung Cancer Aged 75 Years and Older (and in a Cohort of Patients 50 Years Old and Younger)	Completed	NCT00068497		gefitinib
29	Amino Acid Transport Imaging of Parathyroid Adenomas With Anti-3-[18F]FACBC	Completed	NCT01574287		FACBC
30	Evaluating Impact of Near Infrared Autofluorescence (NIRAF) Detection for Identifying Parathyroid Glands During Parathyroidectomy	Recruiting	NCT04299425
31	The Registry of Oncology Outcomes Associated With Testing and Treatment (ROOT)	Recruiting	NCT04028479		Systemic Treatment (T)
32	Prospective Comprehensive Molecular Analysis of Endocrine Neoplasms	Recruiting	NCT01005654
33	Evaluating Impact of Near Infrared Autofluorescence (NIRAF) Detection for Identifying Parathyroid Glands During Parathyroidectomy	Recruiting	NCT05022641
34	Pre-operative Localization of Parathyroid Adenomas Using F-18 PSMA PET/CT: A Pilot Study	Recruiting	NCT05299632
35	Natural History Study of Parathyroid Disorders	Recruiting	NCT04969926
36	Evaluating Impact of Near Infrared Autofluorescence (NIRAF) Detection for Identifying Parathyroid Glands During Parathyroidectomy	Active, not recruiting	NCT05152927
37	Intraoperative Injection of Exparel Effect on Postoperative Opioid Use in Thyroid and Parathyroid Surgery	Enrolling by invitation	NCT04085913	Early Phase 1	Lidocaine Epinephrine;Bupivacaine Hydrochloride-EPINEPHrine;Lidocaine Epinephrine, Bupivacaine Hydrochloride-EPINEPHrine
38	Interactions Between Bone and Parathyroid Tumors in Patiens With Primary Hyperparathyroidism (The PARABONE Study)	Not yet recruiting	NCT05556499
39	Cohort Trial on Perioperative Localization Techniques of Parathyroid Adenomas	Not yet recruiting	NCT04013100
40	Localization of Parathyroid Adenomas Using MRI and SPECT Fusion Software in Patients With Persistent or Recurrent Hyperparathyroidism	Terminated	NCT00639405
41	High Intensity Focused Ultrasound (HIFU) for Parathyroid Adenoma	Terminated	NCT01291498
42	Multicenter Registry Comparing Preoperative Imaging for Primary Hyperparathyroidism	Withdrawn	NCT02381925
43	Ultrasound Guided Fine Needle Aspiration of Parathyroid Gland as a Pre Operative Localization Tool to Identify Pathological Parathyroid	Withdrawn	NCT03516747

Search NIH Clinical Center for Parathyroid Carcinoma

Cochrane evidence based reviews: parathyroid neoplasms

Sources

Genetic Tests for Parathyroid Carcinoma

Genetic tests related to Parathyroid Carcinoma:

#	Genetic test	Affiliating Genes
1	Parathyroid Carcinoma ²⁸	CDC73

Sources

Anatomical Context for Parathyroid Carcinoma

Organs/tissues related to Parathyroid Carcinoma:

FMA: Parathyroid Glands Located In The Neck

MalaCards : Thyroid, Bone, Kidney, Pancreas, Pituitary, Lung, Lymph Node

Sources

Publications for Parathyroid Carcinoma

Articles related to Parathyroid Carcinoma:

(show top 50) (show all 1724)

#	Title	Authors	PMID	Year
1	Somatic and germ-line mutations of the HRPT2 gene in sporadic parathyroid carcinoma. ⁵³ ⁶² ⁵⁷ ⁵	Shattuck TM...Arnold A	14585940	2003
2	Nuclear localization of the parafibromin tumor suppressor protein implicated in the hyperparathyroidism-jaw tumor syndrome enhances its proapoptotic function. ⁵³ ⁶² ⁵	Lin L...Simonds WF	17314275	2007
3	Diagnosis of parathyroid tumors in familial isolated hyperparathyroidism with HRPT2 mutation: implications for cancer surveillance. ⁵³ ⁶² ⁵	Guarnieri V...Cole DE	16720667	2006
4	Genotype of CDC73 germline mutation determines risk of parathyroid cancer. ⁶² ⁵	Li Y...Simonds WF	32590342	2020
5	Large deletion at the CDC73 gene locus and search for predictive markers of the presence of a CDC73 genetic lesion. ⁶² ⁵	Muscarella LA...Guarnieri V	29755684	2018
6	CDC73-Related Disorders: Clinical Manifestations and Case Detection in Primary Hyperparathyroidism. ⁶² ⁵	van der Tuin K...Morreau H	29040582	2017
7	Large intragenic deletion of CDC73 (exons 4-10) in a three-generation hyperparathyroidism-jaw tumor (HPT-JT) syndrome family. ⁶² ⁵	Guarnieri V...Cole DEC	28774260	2017
8	Hyperparathyroidism-jaw tumor syndrome: Results of operative management. ⁶² ⁵	Mehta A...Kebebew E	25444225	2014
9	CDC73 intragenic deletion in familial primary hyperparathyroidism associated with parathyroid carcinoma. ⁶² ⁵	Korpi-Hyovalti E...Schalin-Jantti C	24823466	2014
10	Frequent large germline HRPT2 deletions in a French National cohort of patients with primary hyperparathyroidism. ⁶² ⁵	Bricaire L...GTE Group	23293331	2013
11	Novel HRPT2/CDC73 gene mutations and loss of expression of parafibromin in Chinese patients with clinically sporadic parathyroid carcinomas. ⁶² ⁵	Wang O...Xing X	23029104	2012
12	[Clinical and molecular genetic analyses for a sporadic parathyroid carcinoma]. ⁶² ⁵	Wang CY...Xing XP	20979880	2010
13	The effect of disease-associated HRPT2 mutations on splicing. ⁶² ⁵	Hahn MA...Marsh DJ	19332451	2009
14	Familial isolated hyperparathyroidism is rarely caused by germline mutation in HRPT2, the gene for the hyperparathyroidism-jaw tumor syndrome. ⁶² ⁵	Simonds WF...Marx SJ	14715834	2004
15	HRPT2, a marker of parathyroid cancer. ⁶² ⁵⁷	Weinstein LS...Simonds WF	14585935	2003
16	Clinical review 122: Parathyroid carcinoma. ⁶² ⁵⁷	Shane E	11157996	2001
17	Natural history of parathyroid carcinoma. Diagnosis, treatment, and results. ⁶² ⁵⁷	Wang CA...Gaz RD	3985291	1985
18	Recurrent Hyperparathyroidism Due to a Novel CDC73 Splice Mutation. ⁵	Hattangady NG...Else T	28394026	2017
19	Next-generation sequencing of duplication CNVs reveals that most are tandem and some create fusion genes at breakpoints. ⁵	Newman S...Rudd MK	25640679	2015
20	Prospective enterprise-level molecular genotyping of a cohort of cancer patients. ⁵	MacConaill LE...Lindeman NI	25157968	2014
21	Familial isolated primary hyperparathyroidism/hyperparathyroidism-jaw tumour syndrome caused by germline gross deletion or point mutations of CDC73 gene in Chinese. ⁵	Kong J...Xing X	24716902	2014
22	Splicing in action: assessing disease causing sequence changes. ⁵	Baralle D...Baralle M	16199547	2005
23	A Novel IVS2-1G>A mutation causes aberrant splicing of the HRPT2 gene in a family with hyperparathyroidism-jaw tumor syndrome. ⁵	Moon SD...Cha BY	15613436	2005
24	Germline and de novo mutations in the HRPT2 tumour suppressor gene in familial isolated hyperparathyroidism (FIHP). ⁵	Villablanca A...Larsson C	14985403	2004
25	HRPT2, encoding parafibromin, is mutated in hyperparathyroidism-jaw tumor syndrome. ⁵	Carpten JD...Hobbs MR	12434154	2002
26	Death as a result of asthma in Wayne County Medical Examiner cases, 1975-1987. ⁵	Campbell S...Mirchandani H	2329331	1990
27	Differential expression of microRNAs in human parathyroid carcinomas compared with normal parathyroid tissue. ⁵³ ⁶²	Corbetta S...Spada A	19926710	2010
28	The tumor suppressor, parafibromin, mediates histone H3 K9 methylation for cyclin D1 repression. ⁵³ ⁶²	Yang YJ...Cho EJ	19906718	2010
29	Molecular genetics of parathyroid disease. ⁵³ ⁶²	Westin G...Akerstrom G	19373510	2009
30	Parathyroid carcinoma in multiple endocrine neoplasia type 1 with a classic germline mutation. ⁵³ ⁶²	Shih RY...Wells D	19491073	2009
31	Loss of expression for the Wnt pathway components adenomatous polyposis coli and glycogen synthase kinase 3-beta in parathyroid carcinomas. ⁵³ ⁶²	Juhlin CC...Hoog A	19148484	2009
32	Accuracy of combined protein gene product 9.5 and parafibromin markers for immunohistochemical diagnosis of parathyroid carcinoma. ⁵³ ⁶²	Howell VM...Marsh DJ	19017757	2009
33	Defining a molecular phenotype for benign and malignant parathyroid tumors. ⁵³ ⁶²	Fernandez-Ranvier GG...Clark OH	19107770	2009
34	The parafibromin tumor suppressor protein inhibits cell proliferation by repression of the c-myc proto-oncogene. ⁵³ ⁶²	Lin L...Simonds WF	18987311	2008
35	Primary hyperparathyroidism: a current perspective. ⁵³ ⁶²	DeLellis RA...Mangray S	18684024	2008
36	Expression of parafibromin in distant metastatic parathyroid tumors in patients with advanced secondary hyperparathyroidism due to chronic kidney disease. ⁵³ ⁶²	Tominaga Y...Uchida K	18338208	2008
37	Familial hyperparathyroidism: surgical outcome after 30 years of follow-up in three families with germline HRPT2 mutations. ⁵³ ⁶²	Sarquis MS...De Marco L	18436011	2008
38	Aberrant methylation of the HRPT2 gene in parathyroid carcinoma. ⁵³ ⁶²	Hewitt KM...Hobbs M	18217513	2007
39	Identification of MEN1 and HRPT2 somatic mutations in paraffin-embedded (sporadic) parathyroid carcinomas. ⁵³ ⁶²	Haven CJ...Morreau H	17555500	2007
40	Should parafibromin staining replace HRTP2 gene analysis as an additional tool for histologic diagnosis of parathyroid carcinoma? ⁵³ ⁶²	Cetani F...Marcocci C	17468190	2007
41	Loss of nuclear expression of parafibromin distinguishes parathyroid carcinomas and hyperparathyroidism-jaw tumor (HPT-JT) syndrome-related adenomas from sporadic parathyroid adenomas and hyperplasias. ⁵³ ⁶²	Gill AJ...Marsh DJ	16931959	2006
42	Genetic analyses in patients with familial isolated hyperparathyroidism and hyperparathyroidism-jaw tumour syndrome. ⁵³ ⁶²	Mizusawa N...Yoshimoto K	16817812	2006
43	Parathyroid carcinoma. ⁵³ ⁶²	Rodgers SE...Perrier ND	16357559	2006
44	Identification of a functional bipartite nuclear localization signal in the tumor suppressor parafibromin. ⁵³ ⁶²	Hahn MA...Marsh DJ	16116486	2005
45	Galectin-3 expression in parathyroid carcinoma: immunohistochemical study of 26 cases. ⁵³ ⁶²	Bergero N...Papotti M	16112008	2005
46	Parathyroid carcinoma: an overview. ⁵³ ⁶²	DeLellis RA	15731573	2005
47	Parathyroid carcinoma. ⁵³ ⁶²	Mittendorf EA...McHenry CR	15719375	2005
48	Parafibromin, product of the hyperparathyroidism-jaw tumor syndrome gene HRPT2, regulates cyclin D1/PRAD1 expression. ⁵³ ⁶²	Woodard GE...Simonds WF	15580289	2005
49	Genetic analyses of the HRPT2 gene in primary hyperparathyroidism: germline and somatic mutations in familial and sporadic parathyroid tumors. ⁵³ ⁶²	Cetani F...Marcocci C	15531515	2004
50	Loss of parafibromin immunoreactivity is a distinguishing feature of parathyroid carcinoma. ⁵³ ⁶²	Tan MH...Teh BT	15475453	2004

Sources

Genes for Parathyroid Carcinoma

Genes related to Parathyroid Carcinoma (1 elite genes):

(show all 19)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubMed IDs
1	CDC73	Cell Division Cycle 73	Protein Coding	1434.3	Molecular basis known ⁵⁷ Pathogenic ⁵ Causative somatic mutation ⁵⁸ Genetic Tests ²⁸ Likely pathogenic ⁵ DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Disorders Publications Summaries (show sections)	2329331 12434154 14585940 (more) 14715834 14985403 15613436 16199547 16720667 19332451 20979880 23029104 23293331 24716902 24823466 25444225 29040582 29755684 32590342 17314275 25640679 28394026 15719375 15531515 15580289 17555500 16357559 19926710 17468190 18987311 16931959 19017757 15475453 12960210 18217513 19148484 18338208 19107770 16116486 16964291 18080135 17592260 15731573 20052758 17639063 19522828 18684024 16817812 19906718 17490066 20026646 16728578 17468290 18436011
2	CASR	Calcium Sensing Receptor	Protein Coding	33.12	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	14694525 9543122 16765016
3	PTH	Parathyroid Hormone	Protein Coding	30.77	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	10396361 1609615
4	CTNNB1	Catenin Beta 1	Protein Coding	30	Likely pathogenic ⁵ DISEASES inferred ¹⁴	25157968
5	CCND1	Cyclin D1	Protein Coding	28.76	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	8626826 10229506 14694525 (more) 7906387 19373510 15105644 7621424
6	MEN1	Menin 1	Protein Coding	25.27	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	19491073 10396361
7	CALCA	Calcitonin Related Polypeptide Alpha	Protein Coding	14.01	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
8	UCHL1	Ubiquitin C-Terminal Hydrolase L1	Protein Coding	12.65	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
9	RET	Ret Proto-Oncogene	Protein Coding	12.63	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	8616528
10	LGALS3	Galectin 3	Protein Coding	12.48	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
11	APC	APC Regulator Of WNT Signaling Pathway	Protein Coding	9.88	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
12	MKI67	Marker Of Proliferation Ki-67	Protein Coding	9.57	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	16112008
13	MIR139	MicroRNA 139	RNA Gene	8.17	DISEASES inferred ¹⁴ ¹⁴
14	MIR30B	MicroRNA 30b	RNA Gene	7.91	DISEASES inferred ¹⁴ ¹⁴
15	RB1	RB Transcriptional Corepressor 1	Protein Coding	7.88	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	12864795 14678295
16	GCM2	Glial Cells Missing Transcription Factor 2	Protein Coding	6.58	DISEASES inferred ¹⁴
17	PRUNE2	Prune Homolog 2 With BCH Domain	Protein Coding	6.56	DISEASES inferred ¹⁴
18	CXADR	CXADR Ig-Like Cell Adhesion Molecule	Protein Coding	6.5	Novoseek inferred ⁵³	19237714
19	ADCK1	AarF Domain Containing Kinase 1	Protein Coding	6.42	DISEASES inferred ¹⁴

Sources

Variations for Parathyroid Carcinoma

ClinVar genetic disease variations for Parathyroid Carcinoma:

⁵ (show top 50) (show all 896)

#	Gene	Name	Type	Significance	ClinVarId	dbSNP ID	Position
1	CDC73	NM_024529.5(CDC73):c.128G>A (p.Trp43Ter)	SNV	Pathogenic	3271	rs121434263	GRCh37: 1:193091458-193091458 GRCh38: 1:193122328-193122328
2	CDC73	NM_024529.5(CDC73):c.375dup (p.Arg126fs)	DUP	Pathogenic	3275	rs1572150584	GRCh37: 1:193104668-193104669 GRCh38: 1:193135538-193135539
3	CDC73	NM_024529.5(CDC73):c.685_688del (p.Arg229fs)	MICROSAT	Pathogenic	3278	rs760591174	GRCh37: 1:193111146-193111149 GRCh38: 1:193142016-193142019
4	CDC73	NM_024529.5(CDC73):c.85del (p.Glu29fs)	DEL	Pathogenic	3280	rs587776560	GRCh37: 1:193091412-193091412 GRCh38: 1:193122282-193122282
5	CDC73	NM_024529.5(CDC73):c.13_30del (p.Leu5_Gln10del)	DEL	Pathogenic	3281	rs587776561	GRCh37: 1:193091342-193091359 GRCh38: 1:193122212-193122229
6	CDC73	NC_000001.11:g.(?_193130174)_(193130243_?)del	DEL	Pathogenic	417319		GRCh37: 1:193099304-193099373 GRCh38: 1:193130174-193130243
7	overlap with 20 genes		DEL	Pathogenic	560081		GRCh37: 1:191888324-194584888 GRCh38: 1:191919194-194615758
8	CDC73	NC_000001.11:g.(?_193236246)_(193236366_?)del	DEL	Pathogenic	583777		GRCh37: 1:193205376-193205496 GRCh38: 1:193236246-193236366
9	CDC73	NM_024529.5(CDC73):c.220dup (p.Tyr74fs)	DUP	Pathogenic	801586	rs1572142597	GRCh37: 1:193094327-193094328 GRCh38: 1:193125197-193125198
10	CDC73 and overlap with 1 gene(s)	NC_000001.11:g.(?_193122201)_(193250712_?)del	DEL	Pathogenic	830490		GRCh37: 1:193091331-193219842 GRCh38:
11	CDC73	NC_000001.11:g.(?_193122201)_(193125227_?)del	DEL	Pathogenic	830741		GRCh37: 1:193091331-193094357 GRCh38:
12	CDC73	NC_000001.11:g.(?_193125102)_(193130253_?)del	DEL	Pathogenic	831107		GRCh37: 1:193094232-193099383 GRCh38:
13	CDC73	NC_000001.11:g.(?_193122191)_(193125227_?)del	DEL	Pathogenic	831275		GRCh37: 1:193091321-193094357 GRCh38:
14	CDC73	NC_000001.11:g.(?_193135381)_(193138183_?)del	DEL	Pathogenic	833443		GRCh37: 1:193104511-193107313 GRCh38:
15	CDC73	NC_000001.11:g.(?_193122191)_(193152454_?)del	DEL	Pathogenic	832317		GRCh37: 1:193091321-193121584 GRCh38:
16	CDC73 and overlap with 2 gene(s)	NC_000001.11:g.(?_193122191)_(193250722_?)del	DEL	Pathogenic	647462		GRCh37: 1:193091321-193219852 GRCh38: 1:193122191-193250722
17	CDC73	NM_024529.5(CDC73):c.1405dup (p.Ile469fs)	DUP	Pathogenic	938616	rs1677757559	GRCh37: 1:193205473-193205474 GRCh38: 1:193236343-193236344
18	CDC73	NC_000001.10:g.(?_193099298)_(193099379_?)del	DEL	Pathogenic	1069682		GRCh37: 1:193099298-193099379 GRCh38:
19	CDC73	NC_000001.10:g.(?_193181185)_(193219842_?)del	DEL	Pathogenic	1069683		GRCh37: 1:193181185-193219842 GRCh38:
20	CDC73	NC_000001.10:g.(?_193202113)_(193205496_?)del	DEL	Pathogenic	1069684		GRCh37: 1:193202113-193205496 GRCh38:
21	CDC73	NM_024529.5(CDC73):c.628C>T (p.Gln210Ter)	SNV	Pathogenic	1355843		GRCh37: 1:193111095-193111095 GRCh38: 1:193141965-193141965
22	CDC73	NM_024529.5(CDC73):c.1012C>T (p.Gln338Ter)	SNV	Pathogenic	1353959		GRCh37: 1:193172964-193172964 GRCh38: 1:193203834-193203834
23	CDC73	NM_024529.5(CDC73):c.1072C>T (p.Arg358Ter)	SNV	Pathogenic	1388879		GRCh37: 1:193181525-193181525 GRCh38: 1:193212395-193212395
24	CDC73	NM_024529.5(CDC73):c.893del (p.Phe298fs)	DEL	Pathogenic	1414614		GRCh37: 1:193119497-193119497 GRCh38: 1:193150367-193150367
25	CDC73	NM_024529.5(CDC73):c.1417dup (p.Ile473fs)	DUP	Pathogenic	1405935		GRCh37: 1:193205482-193205483 GRCh38: 1:193236352-193236353
26	CDC73	NM_024529.5(CDC73):c.877dup (p.Tyr293fs)	DUP	Pathogenic	1454174		GRCh37: 1:193119481-193119482 GRCh38: 1:193150351-193150352
27	CDC73	NM_024529.5(CDC73):c.626_629del (p.Lys209fs)	DEL	Pathogenic	1457825		GRCh37: 1:193111092-193111095 GRCh38: 1:193141962-193141965
28	CDC73 and overlap with 1 gene(s)	NC_000001.10:g.(?_193091331)_(193172992_?)del	DEL	Pathogenic	1455935		GRCh37: 1:193091331-193172992 GRCh38:
29	CDC73	NM_024529.5(CDC73):c.1307del (p.Pro436fs)	DEL	Pathogenic	1456450		GRCh37: 1:193202274-193202274 GRCh38: 1:193233144-193233144
30	CDC73	NM_024529.5(CDC73):c.331del (p.Ser111fs)	DEL	Pathogenic	1456469		GRCh37: 1:193104543-193104543 GRCh38: 1:193135413-193135413
31	CDC73	NM_024529.5(CDC73):c.1397del (p.Pro466fs)	DEL	Pathogenic	1459882		GRCh37: 1:193205465-193205465 GRCh38: 1:193236335-193236335
32	CDC73	NM_024529.5(CDC73):c.501_502del (p.Glu168fs)	DEL	Pathogenic	1454960		GRCh37: 1:193107292-193107293 GRCh38: 1:193138162-193138163
33	CDC73	NM_024529.5(CDC73):c.406A>T (p.Lys136Ter)	SNV	Pathogenic	1457823		GRCh37: 1:193104702-193104702 GRCh38: 1:193135572-193135572
34	CDC73	NM_024529.5(CDC73):c.201del (p.His68fs)	DEL	Pathogenic	1452911		GRCh37: 1:193094311-193094311 GRCh38: 1:193125181-193125181
35	CDC73	NM_024529.5(CDC73):c.455_456del (p.Arg152fs)	MICROSAT	Pathogenic	403892	rs1060500019	GRCh37: 1:193107241-193107242 GRCh38: 1:193138111-193138112
36	CDC73	NM_024529.5(CDC73):c.53_54del (p.Ile18fs)	DEL	Pathogenic	567635	rs1558276157	GRCh37: 1:193091383-193091384 GRCh38: 1:193122253-193122254
37	CDC73	NM_024529.5(CDC73):c.1001_1004del (p.Thr334fs)	DEL	Pathogenic	844763	rs1677132309	GRCh37: 1:193172953-193172956 GRCh38: 1:193203823-193203826
38	CDC73	NM_024529.5(CDC73):c.245del (p.Asn82fs)	DEL	Pathogenic	403878	rs1060500009	GRCh37: 1:193099308-193099308 GRCh38: 1:193130178-193130178
39	CDC73	NM_024529.5(CDC73):c.237+1G>C	SNV	Pathogenic	403882	rs794727303	GRCh37: 1:193094348-193094348 GRCh38: 1:193125218-193125218
40	CDC73	NM_024529.5(CDC73):c.7dup (p.Asp3fs)	DUP	Pathogenic	939836	rs1675462891	GRCh37: 1:193091335-193091336 GRCh38: 1:193122205-193122206
41	CDC73	NM_024529.5(CDC73):c.355C>T (p.Gln119Ter)	SNV	Pathogenic	279950	rs886041278	GRCh37: 1:193104568-193104568 GRCh38: 1:193135438-193135438
42	CDC73	NM_024529.5(CDC73):c.10del (p.Val4fs)	DEL	Pathogenic	1069972		GRCh37: 1:193091340-193091340 GRCh38: 1:193122210-193122210
43	CDC73	NM_024529.5(CDC73):c.162C>G (p.Tyr54Ter)	SNV	Pathogenic	3274	rs121434265	GRCh37: 1:193094272-193094272 GRCh38: 1:193125142-193125142
44	CDC73	NM_024529.5(CDC73):c.1052del (p.Pro351fs)	DEL	Pathogenic	462737	rs1553288362	GRCh37: 1:193181212-193181212 GRCh38: 1:193212082-193212082
45	CDC73	NM_024529.5(CDC73):c.483dup (p.Glu162fs)	DUP	Pathogenic	531648	rs1553279085	GRCh37: 1:193107271-193107272 GRCh38: 1:193138141-193138142
46	CDC73	NC_000001.11:g.(?_193122191)_(193150392_?)del	DEL	Pathogenic	830553		GRCh37: 1:193091321-193119522 GRCh38:
47	CDC73	NM_024529.5(CDC73):c.64G>T (p.Gly22Ter)	SNV	Pathogenic	967087	rs1675465013	GRCh37: 1:193091394-193091394 GRCh38: 1:193122264-193122264
48	CDC73	NM_024529.5(CDC73):c.423+1G>A	SNV	Pathogenic	430013	rs1131691732	GRCh37: 1:193104720-193104720 GRCh38: 1:193135590-193135590
49	CDC73	NM_024529.5(CDC73):c.341T>A (p.Leu114Ter)	SNV	Pathogenic	1072177		GRCh37: 1:193104554-193104554 GRCh38: 1:193135424-193135424
50	CDC73	NM_024529.5(CDC73):c.718del (p.Ser240fs)	DEL	Pathogenic	660497	rs1572154885	GRCh37: 1:193111183-193111183 GRCh38: 1:193142053-193142053

Sources

Expression for Parathyroid Carcinoma

Search GEO for disease gene expression data for Parathyroid Carcinoma.

Sources

Pathways for Parathyroid Carcinoma

Pathways directly related to Parathyroid Carcinoma:

#	Pathway	Source
1	Signaling by LRP5 mutants	Reactome ⁶⁶

Pathways related to Parathyroid Carcinoma according to GeneCards Suite gene sharing:

(show all 15)

#	Super pathways	Score	Top Affiliating Genes
1	Signal Transduction ⁶⁶	13.39	RET PTH MEN1 CTNNB1 CDC73 CCND1
2	Neuroscience ³	12.38	UCHL1 RET MKI67 CALCA
3	DNA Damage ³	12.27	RB1 MKI67 CDC73 CCND1
4	Breast cancer pathway ⁷⁴ Show member pathways Embryonic stem cell pluripotency pathways ⁷⁴	12.19	RB1 CTNNB1 CCND1 APC
5	WNT Signaling ⁶⁴	12.18	RB1 CTNNB1 CCND1 APC
6	Spinal cord injury ⁷⁴	11.77	RB1 LGALS3 CCND1
7	DNA damage response (only ATM dependent) ⁷⁴	11.69	CTNNB1 CCND1 APC
8	Head and neck squamous cell carcinoma ⁷⁴	11.47	RB1 CTNNB1 CCND1
9	Regulation of nuclear beta catenin signaling and target gene transcription ⁶¹	11.44	APC CCND1 CTNNB1
10	Endoderm differentiation ⁷⁴	11.4	CTNNB1 CDC73 APC
11	Overlap between signal transduction pathways contributing to LMNA laminopathies ⁷⁴ Show member pathways Influence of laminopathies on Wnt signaling ⁷⁴	11.23	RB1 CTNNB1 CCND1 APC
12	Presenilin action in Notch and Wnt signaling ⁶¹	11.1	CTNNB1 CCND1 APC
13	Deactivation of the beta-catenin transactivating complex ⁶⁶	10.96	MEN1 CTNNB1 APC
14	Regulation of Wnt / B-catenin signaling by small molecule compounds ⁷⁴	10.73	CTNNB1 APC
15	H19 action Rb-E2F1 signaling and CDK-Beta-catenin activity ⁷⁴	9.95	RB1 CTNNB1 CCND1

Sources

GO Terms for Parathyroid Carcinoma

Cellular components related to Parathyroid Carcinoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	bicellular tight junction	GO:0005923	9.23	CXADR CTNNB1 CCND1 APC

Biological processes related to Parathyroid Carcinoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	negative regulation of epithelial cell proliferation	GO:0050680	9.8	RB1 MEN1 CDC73
2	negative regulation of G1/S transition of mitotic cell cycle	GO:2000134	9.63	RB1 CDC73 APC
3	response to fibroblast growth factor	GO:0071774	9.56	PTH CASR
4	endodermal cell fate commitment	GO:0001711	9.26	CTNNB1 CDC73
5	cellular calcium ion homeostasis	GO:0006874	9.17	PTH GCM2 CASR CALCA